News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article reports that Ensysce Biosciences Inc. filed a Form 8K on August 13. The company's stock symbol is ENSC, which saw a 14.75% increase. The article provides only this financial filing information without further details on the content of the Form 8K.
Ensysce Biosciences announced its Q2 2026 financial results, highlighted by the acquisition of Cy Biopharma, Inc., which adds CY200 for Complex Regional Pain Syndrome (CRPS) to its pipeline. This acquisition, coupled with private placement financings, provides up to $77 million in new funding, extending …
Nortech Systems Inc (NSYS) reported a 9.3% increase in net sales to $33.5 million for Q2 2026, alongside a slight rise in net income. Despite revenue growth, the company faces operational challenges with a 24.1% jump in operating expenses. GuruFocus assesses NSYS as overvalued …
* Nortech Systems press release [https://seekingalpha.com/pr/20617339-nortech-systems-reports-second-quarter-results] (NSYS [https://seekingalpha.com/symbol/NSYS]): Q2 GAAP EPS of $0.11. * Revenue of $33.5M (+9.1% Y/Y). MORE ON NORTECH SYSTEMS * Nortech Systems Incorporated (NSYS) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4904874-nortech-systems-incorporated-nsys-q1-2026-earnings-call-transcript] * Nortech outlines $15M asset-backed credit line as backlog reaches …
Nortech Systems (Nasdaq:NSYS) reported solid Q2 2026 financial results, with net sales increasing 9.3% to $33.5 million and net income remaining largely flat at $316 thousand. The company's total backlog grew 20% year-over-year to $93.8 million, indicating strong future business prospects, particularly in Aerospace …
Nortech Systems (NSYS) reported a significant financial turnaround for the first half of 2026, swinging to a net profit of $0.3 million from a $1.0 million loss a year prior. This improvement was driven by a 10.9% increase in net sales to $63.9 million, …
Ensysce Biosciences' President, James William Morrison, reported an indirect holding of 154,821 Series C Non-Voting Convertible Preferred Stock shares through Belgarion Ventures Ltd. These preferred shares are convertible into 154,821,000 common shares, contingent on stockholder approval and Nasdaq rules, with a beneficial ownership limitation. …
This article provides an earnings forecast for Nortech Systems Inc (NSYS), detailing future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, P/E ratio, and lists peer comparisons with other technology equipment and semiconductor companies. The …
This article provides the current stock information for Nortech Systems Inc (NSYS), including its latest stock price, market cap, and P/E ratio. It indicates that more news will be available soon and encourages users to stay tuned for updates on earnings, analyst ratings, and …
Ensysce Biosciences (NASDAQ: ENSC) has acquired Cy Biopharma Inc. and secured up to $77 million in financing, combining their pain management portfolios. This deal aims to advance a late-stage pipeline, including Cy Biopharma’s lead candidate CY200 for Complex Regional Pain Syndrome Type 1, which …
Ensysce Biosciences has acquired Cy Biopharma in a deal valued at up to $77 million, significantly broadening its focus beyond opioids into neuroplastogenic pain therapeutics. This acquisition transforms Ensysce into a more diverse pain management company, incorporating Cy Biopharma's clinical-stage neuroplastogenic program, CY200, for …
This article from Investing.com reports on Ensysce Biosciences Inc's Form 8K filing for August 6th. The filing is a standard requirement by the SEC for significant events that shareholders should know about. The brief article indicates that Ensysce Biosciences Inc. (ENSC) has seen a …
Ensysce Biosciences, Inc. (NASDAQ: ENSC) has completed its acquisition of Cy Biopharma, Inc., a clinical-stage biotech company focused on neuroplastogenic therapies for complex pain. This acquisition, which includes $17.1 million in cash from pre-acquisition financing, is accompanied by a private placement expected to generate …
Ensysce Biosciences has acquired Cy Biopharma, gaining CY200, a clinical-stage therapy with FDA Orphan Drug Designation for Complex Regional Pain Syndrome Type 1. The acquisition includes $17.1 million in cash from Cy Biopharma and a private placement expected to raise approximately $43 million in …
Ensysce Biosciences (ENSC) stock surged 52.6% in pre-open trading after the company announced a formal strategic review to explore partnerships, licensing deals, or asset sales. This move follows positive corporate developments, including a $5.3 million award from the National Institute on Drug Abuse and …
Ensysce Biosciences (NASDAQ:ENSC) saw its shares surge by 48% in premarket trading, but still needs a 141% increase to meet Nasdaq's $1 minimum bid price requirement. The company faces delisting concerns due to its low stock price and a deficit in stockholders' equity, and …
Nortech Systems Incorporated announced it will release its second-quarter 2026 financial results on August 12, 2026. The company will host a conference call and webcast led by CEO Jay D. Miller and CFO Andrew D. C. LaFrence to discuss these results. This event is …
Nortech Systems (Nasdaq: NSYS) will hold a live conference call and webcast on August 12, 2026, at 3:30 p.m. Central Time, to discuss its second quarter 2026 financial results. CEO Jay D. Miller and CFO Andrew D. C. LaFrence will host the call, which …
This article lists 12 healthcare stocks that experienced significant movement during Monday's after-market trading session. It details both gainers, such as Ensysce Biosciences and TransCode Therapeutics, and losers, including Addex Therapeutics and ClearPoint Neuro, providing their stock performance, current prices, and market capitalizations. The …
This article provides a risk assessment for Nortech Systems Inc (NSYS), noting its current risk score of 2.76, which ranks it 85 out of 104 in the Semiconductors & Semiconductor Equipment industry. The company's beta of 0.05 suggests it is less volatile than the …
Ensysce Biosciences Inc (ENSC) has a weak financial status and low operating efficiency, ranking 260 out of 384 in the Biotechnology & Medical Research industry with a financial score of 6.34. The company's latest quarterly revenue decreased by 27.18% year-over-year to $961.00K, and its …
Nortech Systems Inc (NSYS) currently has an institutional shareholding score of 3.00, placing it 76th out of 105 companies in the Semiconductors & Semiconductor Equipment industry. The institutional shareholding proportion is 4.05%, showing a 7.57% increase quarter-over-quarter. James Simons is the largest institutional shareholder, …
Search by ticker symbol or company name and select a result to open its chart.